Benzinga reports that stock analysts at the Royal Bank of Canada lowered their price target for Viracta Therapeutics (NASDAQ: VIRX) on Friday from $10.00 to $8.00. The previous price target was $10.00. The price target before this one had been set at $10.00. The company’s stock was just given the rating of “outperform” by the analyst. If we compare the price target of the Royal Bank of Canada to the stock’s most recent closing price, we see that there is a possibility that the price target will be higher by 141.33 percent.

On August 9, the most recent earnings report for Viracta Therapeutics was made public. Virata Therapeutics’ shares are traded on the NASDAQ under the ticker symbol VIRX. On August 9, the company reported earnings per share for $0.28, which was $0.02 better than the average expectation of $0.30. In addition, the company announced earnings per share for $0.28, which is $0.02 lower than the consensus estimate of $0.30 per share. As a result, the majority opinion held by specialists in the relevant field predicts that Viracta Therapeutics will report a loss of $1.18 per share for the current fiscal year.
Ivor Royston, who formerly served as the Chief Executive Officer of Viracta Therapeutics, sold 13,379 shares of the company’s stock on Friday, August 26. The price paid for each share, which totaled $53,649.79 after being sold, was $4.01, making the average share price. Because of the purchase, the CEO now owns 612,770 shares. Based on the current market price, these shares are worth $2,457,207.70. Because of the filing with the SEC, information regarding the transaction is now available to the general public. On the website of the SEC, you can locate this particular file. Insiders of the company have sold 19,224 shares over the past three months, resulting in a total profit of $77,125. The employees and management of the company own a combined total of 27.63% of the total shares issued by the company.

On Friday, the NASDAQ VIRX opened for trading for $3.32. 96 is the value reached when the current ratio, the quick ratio, and the debt-to-equity ratio are all added up. The ratio of debt to equity is 0.07 right now. The share price currently sits at $4.28 on its simple moving average for the past fifty days, while its simple moving average for the past 200 days is $3.57. During the previous year, the cost of Viracta Therapeutics experienced a price range that went from an all-time low of $1.82 to an all-time high of $6.09. The company’s market capitalization is $124.51 million, and it has a price-to-earnings ratio of 2.61. Additionally, its beta value is 1.27.

In the most recent few months, various institutional investors have adjusted the interests they hold in the company. These investors hold stakes in the company. MAI Capital Management spent about one and a half million and thirty thousand dollars during the first three months of this year to acquire a new stake in Viracta Therapeutics. Veritable L.P. made a new investment in Viracta Therapeutics during the first three months of 2018, and the total cost of this investment was close to 118 thousand dollars. The value of State Street Corporation’s holdings in Viracta Therapeutics increased by 2.3% over the first three months of 2018. State Street Corp. now owns 588,603 of the company’s shares, which have a combined market value of $2,802,000 after purchasing an additional 13,514 shares during the most recent quarter. This brings the total number of shares that State Street Corp. During the second quarter, Clear Harbor Asset Management LLC opened a new position in Viracta Therapeutics for a total investment of approximately $97,000. During the second quarter, Ensign Peak Advisors Inc. increased the amount of Viracta Therapeutics stock owned by 4.8%, making this the last and most important point. The number of shares of the company’s stock that Ensign Peak Advisors Inc. owns has increased to 63,406 from 62,891 at the end of the most recent quarter. The total value of Ensign Peak Advisors, Inc.’s stock holdings as of the most recent close of the market is $246,000. A total of 30.36% of the total number of shares outstanding in the company are held by institutional investors and hedge funds.

Pharmaceuticals are being developed by Viracta Therapeutics, Inc., a company that specializes in precision oncology. These pharmaceuticals are intended to treat cancers that are caused by viruses. An open-label Phase, two-basket trial for the treatment of various relapsed or refractory Epstein-Barr virus-positive (EBV+) lymphomas is currently being conducted as part of a Phase II clinical trial for Epstein-Barr virus-positive lymphoma. This trial aims to evaluate the efficacy of the investigational treatment in patients with lymphomas who have previously been treated for Epstein-Barr virus-positive lymphoma. It is also planned to conduct an open-label Phase 1b/2 trial with the medications naval, entinostat, and valganciclovir for the treatment of EBV+ patients who have recurrent or metastatic disease.

The post Maxim Group has raised its price target on Tetra Tech (NASDAQ:TTEK) to $200.00. appeared first on Best Stocks.